These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35912841)

  • 1. Long-acting ocular drug delivery technologies with clinical precedent.
    O'Brien Laramy MN; Nagapudi K
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1285-1301. PubMed ID: 35912841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug eluting implants in pharmaceutical development and clinical practice.
    Johnson AR; Forster SP; White D; Terife G; Lowinger M; Teller RS; Barrett SE
    Expert Opin Drug Deliv; 2021 May; 18(5):577-593. PubMed ID: 33275066
    [No Abstract]   [Full Text] [Related]  

  • 3. Biodegradable implants for sustained drug release in the eye.
    Lee SS; Hughes P; Ross AD; Robinson MR
    Pharm Res; 2010 Oct; 27(10):2043-53. PubMed ID: 20535532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically established biodegradable long acting injectables: An industry perspective.
    Nkanga CI; Fisch A; Rad-Malekshahi M; Romic MD; Kittel B; Ullrich T; Wang J; Krause RWM; Adler S; Lammers T; Hennink WE; Ramazani F
    Adv Drug Deliv Rev; 2020 Dec; 167():19-46. PubMed ID: 33202261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Chen YS; Jin J; Rupenthal ID
    Expert Opin Drug Deliv; 2016 Jul; 13(7):953-62. PubMed ID: 26967153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advancemnts in Biodegradable Ocular Implants.
    Mittal S; Miranda O
    Curr Drug Deliv; 2018 Feb; 15(2):144-154. PubMed ID: 28482784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular Drug Delivery: Present Innovations and Future Challenges.
    Gote V; Sikder S; Sicotte J; Pal D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases.
    Shatz W; Aaronson J; Yohe S; Kelley RF; Kalia YN
    Expert Opin Drug Deliv; 2019 Jan; 16(1):43-57. PubMed ID: 30488721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in ocular drug delivery: emphasis on the posterior segment.
    Kang-Mieler JJ; Osswald CR; Mieler WF
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.
    Yasin MN; Svirskis D; Seyfoddin A; Rupenthal ID
    J Control Release; 2014 Dec; 196():208-21. PubMed ID: 25307997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smart design of patient-centric long-acting products: from preclinical to marketed pipeline trends and opportunities.
    Bassand C; Villois A; Gianola L; Laue G; Ramazani F; Riebesehl B; Sanchez-Felix M; Sedo K; Ullrich T; Duvnjak Romic M
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1265-1283. PubMed ID: 35877189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro.
    Liu W; Lee BS; Mieler WF; Kang-Mieler JJ
    Curr Eye Res; 2019 Mar; 44(3):264-274. PubMed ID: 30295090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent perspectives on the delivery of biologics to back of the eye.
    Joseph M; Trinh HM; Cholkar K; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 May; 14(5):631-645. PubMed ID: 27573097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anterior eye segment drug delivery systems: current treatments and future challenges.
    Molokhia SA; Thomas SC; Garff KJ; Mandell KJ; Wirostko BM
    J Ocul Pharmacol Ther; 2013 Mar; 29(2):92-105. PubMed ID: 23485091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.
    Hartnett TE; O'Connor AJ; Ladewig K
    Expert Opin Drug Deliv; 2015; 12(9):1513-26. PubMed ID: 25745885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI in ocular drug delivery.
    Li SK; Lizak MJ; Jeong EK
    NMR Biomed; 2008 Nov; 21(9):941-56. PubMed ID: 18186077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Port delivery system: a novel drug delivery platform to treat retinal diseases.
    Khanani AM; Aziz AA; Weng CY; Lin WV; Vannavong J; Chhablani J; Danzig CJ; Kaiser PK
    Expert Opin Drug Deliv; 2021 Nov; 18(11):1571-1576. PubMed ID: 34388956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.
    Kang-Mieler JJ; Dosmar E; Liu W; Mieler WF
    Expert Opin Drug Deliv; 2017 May; 14(5):611-620. PubMed ID: 27551742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical, biomedical and ophthalmic applications of biodegradable polymers (BDPs): literature and patent review.
    Osi B; Khoder M; Al-Kinani AA; Alany RG
    Pharm Dev Technol; 2022 Mar; 27(3):341-356. PubMed ID: 35297285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.